Candel Therapeutics to Present Extended Phase 3 Data for Prostate Cancer Therapy
Event summary
- Candel Therapeutics will present extended Phase 3 trial data for aglatimagene besadenovec in localized prostate cancer at the AUA 2026 Annual Meeting.
- Investor conference call scheduled for May 15, 2026, featuring insights from leading prostate cancer specialists.
- Aglatimagene besadenovec has received Fast Track and RMAT designations from the FDA for localized prostate cancer.
- Candel's multimodal immunotherapy platforms include adenovirus and herpes simplex virus-based treatments.
The big picture
Candel Therapeutics' presentation of extended Phase 3 data for aglatimagene besadenovec comes at a critical juncture in the prostate cancer treatment landscape. The company's multimodal immunotherapy approach aims to address unmet needs in intermediate- to high-risk localized prostate cancer, a segment with significant market potential. The strategic involvement of key opinion leaders in the field underscores the importance of these data in shaping future treatment paradigms.
What we're watching
- Regulatory Pathway
- Whether the extended Phase 3 data will strengthen aglatimagene besadenovec's regulatory approval prospects.
- Market Positioning
- How Candel Therapeutics positions itself against competitors in the prostate cancer treatment space.
- Clinical Efficacy
- The long-term efficacy and safety profile of aglatimagene besadenovec in intermediate- to high-risk localized prostate cancer.
Related topics